C 2 ,D 2 -sphingosine (SPH) was orally administered to mice to assess absorption, mass balance, tissue distribution, and metabolites in the skin. The blood concentration of 3 H-SPH showed a Tmax of 10.7 hr. The radioactivity in the skin reached 763.4 ng eq./g tissue at 12 hr, and decreased to 181.7 ng eq./g tissue at 168 hr. The concentration of radioactivity at 12 hr was 577.6 and 100.7 ng eq./g tissue in the dermis and epidermis, respectively. Thereafter, the dermis concentration decreased to 158.5 ng eq./g tissue, while the epidermis concentration increased to 298.8 ng eq./g tissue, suggesting that radioactivity moves from the dermis to the epidermis. Unchanged SPH along with lipophilic metabolites was detected in the skin of mice exposed orally to 3 H-or 13 C2,D2-SPH. Moreover, in an in vitro study using human skin keratinocytes, a 13 C2,D2-SPH-treatment resulted in the intracellular production of glucosylceramides (GlcCer) and ceramides (Cer) containing labeled-SPH. These results indicate the followings: first, that SPH is absorbed through the digestive tract and distributed to the skin; second, it is transferred from the dermis to the epidermis; and third, SPH is partly distributed to the skin in an unchanged form, and some of the distributed compounds are converted into GlcCer and Cer by biosynthesis.
Introduction
Ceramides (Cer) are sphingolipids each having a structure with sphingoid bases amide-linked to long-chain fatty acids. In the skin, Cer, which are generated by releasing glucose or phosphorylcholine from GlcCer and sphingomyelins (SM) during the cornification process, form lamellar membrane structures along with cholesterol, cholesterol ester, and free fatty acids in the intercellular space of the stratum corneum; therefore, they have important physiochemical roles as skin barrier functions and moisturizing. [1] [2] [3] Sphingosine (SPH), the backbone of sphingolipids such as Cer, on the other hand, has attracted attention due to its phosphorylated form, shingosine-1-phosphate, for their roles in controlling many biological functions such as differentiation 4) and apoptosis. 5, 6) Although it is widely distributed in the body, SPH is not synthesized de novo and can only be produced by degradation of Cer or supplied in the form of a metabolite of GlcCer and SM present in the diet. Such orally-ingested sphingolipids are known to be partially metabolized into Cer and then further metabolized into fatty acids and sphingoid bases in the digestive tract and subsequently absorbed. [7] [8] [9] Several studies demonstrate that aging, atopic dermatitis, or other metabolic abnormalities involving complex sphingolipid lead to diminished Cer level in the stratum corneum, which compromises cutaneous barrier function and induces skin disorders such as dry skin, redness, and swelling. [10] [11] [12] In recent years, oral ingestion of GlcCer, which can be found in rice, wheat, Amorphophallus konjac, and other grains, has reportedly been shown to be effective in improving cutaneous barrier function, alleviating dry skin, and moderating atopic dermatitis, and this finding has caused interest in sphingolipid as a functional food ingredient. [13] [14] [15] Functional foods influence the whole body gradually but continuously and high QOL is expected in their intake in comparison with the application of topical products which have been applied to the body surface widely. Their possible mechan- isms of action are as follows: ingested GlcCer is metabolized in the gastrointestinal tract, and then sphingoid bases and other metabolites such as Cer are absorbed and distributed to the skin. Furthermore, the sphingoid bases distributed to the skin exhibit beneficial effects to the skin, including raising the epidermal Cer level 16) and inhibiting increase in the level of IL-1a, 17) an inflammatory cytokine that exacerbates skin roughness. Nevertheless, details of its mechanism remain largely unknown. Furthermore, very little pharmacokinetic data are available to corroborate the beneficial effects of sphingoid bases to the skin, for example, distribution of absorbed sphingoid base to skin. With that in mind, we conducted this study to assess the disposition of SPH in vivo by focusing on its distribution to the skin.
Materials and Methods
Chemicals: Figure 1A . The radiochemical purity determined by HPLC was 99.1%, and the specific activity was 740 GBq/mmol. Unlabelled SPH was purchased from Sigma Chemical Co. (St. Louis, MO). Animals: Male HR-1 mice (8 weeks old, 25-29 g) were purchased from Hoshino Laboratory Animals, Inc. (Ibaraki, Japan). These animals were fed the AIN-93G purified diet (Oriental Yeast Co., Ltd., Tokyo, Japan) and water ad libitum. Environmental conditions were controlled at 23±39 C for temperature and 55±15% for relative humidity. H-SPH was diluted with unlabelled compounds, and prepared as an aqueous suspension in 1% tragacanth gum. Each mouse received the suspension as a single oral dose equivalent to 4.4 MBq/4 mg/kg. 13 C2,D2-SPH was not diluted with unlabelled compounds, and each mouse received repeated oral administrations at 10 mg/kg every 24 hr for five days. The present study was approved by the ethics committee of Shiseido Research Center in accordance with the guidelines of the National Institute of Health.
Whole blood concentration: After oral administration of 3 H-SPH to non-fasted mice, blood samples (30 mL) were serially collected from the tail vein at 2, 4, 8, 12, 24, 48, 72, 96, 120 , and 168 hr. The whole blood was weighed and dried at 409 C for 48 hr to remove 3 H2O and combusted using a sample oxidizer (Tri-Carb 307; PerkinElmer Life Sciences, Inc., Boston, MA). The radioactivity in each sample was counted after the addition of 15 mL liquid scintillator (Monophase-S; PerkinElmer Life Sciences, Inc.). The concentrations of total radioactivity in whole blood were expressed as ng equivalents of SPH per mL of whole blood. The half-life (T1/2) on the elimination phase after dosing was calculated by the least squares method. The area under the whole blood concentration-time curve up to the terminal measurement time (AUC0-168) was calculated by the trapezoidal method.
Mass balanced study: Each mouse was kept in a metabolic cage 3600M021 (Tecniplast Japan Co., Ltd., Tokyo, Japan) after dosing of 3 H-SPH and urine and feces were collected separately at various intervals for up to 168 hr. At the end of the collection period, the mice were euthanized by anesthesia and whole skin was removed from each carcass. Suitable portions of urine and feces homogenized in distilled water were combusted by the sample oxidizer. The skin and carcasses were solubilized with 10% (w/v) sodium hydroxide aqueous solution and portions of the solution were combusted with the sample oxidizer.
Distribution study: After oral administration of 3 H-SPH to non-fasted mice, the animals were anesthetized with pentobarbital at 12, 48, 96, and 168 hr. Blood was drawn from the abdominal vein into a heparinized tube, and the following tissues and organs were collected: cerebrum, heart, lung, liver, pancreas, spleen, kidney, muscle, fat, skin, stomach, small intestine, and large intestine. These samples were weighed and dried at 409 C for 48 hr, and combusted using a sample oxidizer. The radioactivity was counted after the addition of 15 mL of liquid scintillator. The dorsal skin was dissected and subcutaneous tissues were scraped off with scissors. After the skin was heated at 609 C for 90 sec and cooled off quickly, the epidermis and dermis were separated with tweezers. The epidermis and portions of the dermis were combusted using the sample oxidizer and radioactivity was counted after the addition of 15 mL liquid scintillator. H-SPH, the mice were anesthetized with pentobarbital at 12 and 96 hr after oral administration, and blood was drawn from the abdominal vein and following skins were collected. In the case of 13 C2,D2-SPH, the skins of mice were collected at 12 hr after the final administration. Scraped sheets of skin free from subcutaneous tissues were cut into pieces with scissors and then homogenized with a Freezer/Mill 6700 } (SPEX CertiPrep, Inc., Metuchen, NJ). 5 mL chloroform/methanol (1:1, v/v) were added to the mixture, followed by sonication for 20 min and vortexing for 20 min. After centrifugation at 2,000×g for 15 min, the organic layer was taken and evaporated to dryness in nitrogen gas. The dried residue was dissolved in 100 mL methanol, and 5 mL of which were injected into the HPLC or LC/MS/MS.
Measurement of radioactivity:
The radioactivity in each sample was determined using a liquid scintillation counter (LS-6000TA; Beckman Coulter, Inc., Fullerton, CA, USA) with automatic quench correction by an external standard method.
Cell Culture: Human neonatal keratinocytes were purchased from Kurabo (Osaka, Japan). The cells were cultured in serum-free keratinocyte growth medium Humedia-KG2 (Kurabo). All in vitro cell culture measurements were carried out using human neonatal keratinocytes at the second to fourth passage. Keratinocytes were cultured in 12 multi-well plates coated with TYPE-I collagen with a density of 2,500 cells/cm 2 . The cells were cultured in 0.15 mM Ca 2＋ medium, HuMedia-KG2 (Kurabo). After 70%-80% confluence, the cells were cultured in 1.8 mM Ca 2＋ medium to induce differentiation for four days. After treatment, the culture medium was removed, and the cells were treated in 1.8 mM Ca-KG2 containing unlabeled SPH or 13 C2,D2-SPH (final 0.1, 1 or 10 mM) for 72 hr. The cells grown in culture dishes were harvested and resuspended in 1 mL phosphate-buffered saline (pH 7.2). A 5-mL aliquot of chloroform/methanol (4:1, v/v) was added to the cell suspension, followed by vortex for 20 min. After centrifugation at 2,000×g for 15 min, the organic layer was taken and evaporated to dryness under nitrogen gas. The dried residue was dissolved in 100 mL methanol, and 5 mL of which were injected into the LC/MS/MS.
HPLC and LC/MS/MS: Radioactive compounds in the skin after oral administration of 3 H-SPH were analyzed by HPLC equipped with a fraction collector system. HPLC was performed in Nanospace SI-2 (Shiseido, Tokyo, Japan) chromatography fitted with Capcell Pak C18 MG column (5 mm, 150×2.0 mm, Shiseido, Tokyo, Japan) maintained at 509 C. A mobile phase consisting of solvent A (0.1% ammonium formate/methanol (2:8)) and solvent B (methanol) was delivered in a gradient from 20% A and 80% B to 2% A and 98% B over 25 min, then held at 98% B for 5 min at a flow rate of 0.3 mL/min. The eluates were collected every 20 sec and counted for radioactivity. The radioactivity peaks were identified by comparison with the retention times of the authentic standards, i.e. SPH, some GlcCer, some Cer, and SM.
LC/MS/MS was performed in an API4000 Q-TRAP } (Applied Biosystems, Foster City, CA) equipped with HPLC (Prominence UFLC; Shimadzu, Kyoto, Japan). For determination of SPH, separation was achieved on a Capcell Pak C18 MG column (5 mm, 150×2.0 mm, Shiseido, Tokyo, Japan) maintained at 409 C. A mobile phase consisting of 0.1% formic acid/methanol (2:8) was delivered at a flow rate of 0.2 mL/min. The tandem mass spectrometer was operated at positive electrospray ionization (ESI) with a 4.5 kV ionization potential and an ion source temperature of 4509 C. The multiple reaction monitoring (MRM) transition ions were m/z 300/282 (Q1/Q3) for SPH and m/z 304/286 for 13 C2,D2-SPH. Mass spectrometric analysis was performed using this system. For determination of GlcCer and Cer, separation was achieved on a Capcell Pak C8 DD column (3 mm, 75× 4.6 mm, Shiseido, Tokyo, Japan) maintained at 509 C. A mobile phase consisting of solvent A (water/methanol (1:9, v/v)) and solvent B (methanol) was delivered in a gradient from 100% A and 0% B to 0% A and 100% B over 15 min, then held at 100% B for 5 min at a flow rate of 0. C2,D2-C24Cer. Mass spectrometric analysis was also performed using this system. Data acquisitions were ascertained by Analyst 1.5 software.
Results

Concentrations of total radioactivity in blood:
Mean concentrations of total radioactivity in whole blood were determined after a single oral administration of 3 H-SPH to mice at a dose of 4 mg/kg (Fig. 2) . Cmax, Tmax and AUC0-168 were 282.9±32.1 ng eq./mL, 10.7±2.3 hr and 20.02±1.64 mg eq.･hr/mL, respectively. The elimination of radioactivity in blood was slow, with T1/2(48-168 hr) of 88.60±12.41 hr.
Urinary and fecal excretion: The results of cu- Each value represents the mean±SD of three animals. Each value represents the mean±SD of four animals. mulative urinary and fecal excretion of total radioactivity after a single oral administration of 3 H-SPH to mice at a dose 4 mg/kg are shown in Table 1 . Urinary and fecal recoveries of radioactivity for the first 24 hr were 9.05% and 34.23%, respectively, of the dosed radioactivity. Most excretion was completed by 72 hr after dosing. The radioactivity recovered within 168 hr was 21.93% in urine and 65.08% in feces. The amount of radioactivity remaining in the skin and carcass at 168 hr after dosing was 0.72% and 7.80%, respectively, of the dosed radioactivity.
Tissue distribution of radioactivity: The tissue concentrations of radioactivity were measured at 12, 48, 96, and 168 hr after a single oral administration to mice ( Table 2) . At 12 hr after dosing, the small intestine exhibited the highest concentration of radioactivity (7141.4 ng eq./g tissue), followed by the liver, lung, large intestine, kidney and skin. At 48 and 96 hr, all tissues exhibited high concentration compared to the plasma, and radioactivity in most tissues except the pancreas and fat decreased to 168 hr. In the skin, at 12 hr after dosing, the concentration of radioactivity reached Cmax of 763.4 ng eq./g tissue and decreased to 181.7 ng eq./g tissue at 168 hr. The decrease in radioactivity in skin was relatively slow compared to that in plasma.
Skin distribution of radioactivity: The distribution of radioactivity in the skin was examined at 12, 48, 96, and 168 hr after oral administration to mice (Fig. 3) . At 12 hr after dosing, the dermis had the highest levels of radioactivity, with a radioactive concentration of 577.6 ±41.0 ng eq./g tissue, accounting for 99.0% of the radioactivity detected in the whole skin. The concentration in the epidermis was 100.7±45.9 ng eq./g tissue, accounting for 1.0% of the radioactivity detected in the whole skin. Radioactivity in dermis continuously decreased to 168 hr, in contrast, radioactivity in epidermis continuously increased to 168 hr. At 168 hr after dosing, the concentration of radioactivity in dermis was 158.5±12.0 ng eq./g tissue, and that in the epidermis was 298.8±17.0 ng eq./g tissue, accounting for 11.8% of the radioactivity in the whole skin.
Skin Metabolite: Metabolites in the skin after an oral dose of 3 H-SPH were analyzed by HPLC (Fig. 4) . At 12 hr after administration, high polar metabolites were detected with a retention time of 1.3 min along with the SPH near 5.7 min, and several low polar metabolites at and subsequent to 23 min. The ratio of unchanged SPH was 16.5±5.3% and 3.5±2.9% of total radioactivity in the skin extract, respectively, at 12 and 96 hr post-dose. A retention-time comparison with the reference standard suggested that several fatty acids were contained in the high polar metabolites and the low polar metabolites consisted of several sphingolipids, including some GlcCer, Cer, and SM. Nevertheless, due to the presence of endogenous sphingolipids and its metabolites in the skin extracts, the sphingolipids detected could not be traced to the SPH in the administered dose.
To allow differentiation between administered SPH and endogenous SPH in the skin, this study used a stable isotope-labeled SPH ( 
C2,D2)＋H-H2O]
＋ at m/z 286, indicating that assays of 13 C2,D2-SPH are not subject to interference from endogenous SPH (Fig. 5) . With this knowledge, skin extracts obtained from mice exposed to repeated oral dose of C2,D2-SPH, however, was detected from the skin extracts of mice exposed to 13 C2,D2-SPH (Fig. 6) . Moreover, analyses of several sphingolipids on LC/MS/MS using APCI detected endogenous C16GlcCer, C18GlcCer, C24GlcCer, C16Cer, C18Cer, and C24Cer in both control animals and mice exposed to 13 C2,D2-SPH. On the other hands, 13 C2,D2-SPH-incorporated C16GlcCer ( 13 C2,D2-C16GlcCer), however, was detected only in skin extracts from mice exposed to 13 C2,D2-SPH (Fig. 7) . Also detected in the same manner were sphingolipids, including ＋ at m/z 264 (Fig. 8A) . The mass spectrum of C16GlcCer for cells cultured in (Fig. 8B) . ＋ at m/z 264 (Fig. 9A) . The mass spectrum of C16Cer for cells cultured in 
C2,D2)＋ H-RCO-H2O]
＋ at m/z 543, m/z 525, m/z 507, and m/z 268, respectively, along with the spectrum from endogenous C16Cer (Fig. 9B) . In contrast, LC/MS/MS analyses of the GlcCer NP species and Cer NP species, both of which are sphingolipids that contain phytosphingosine as shingoid base, 18, 19) indicated no incorporation of the stable isotope.
Quantifications were also performed on intracellular GlcCer NS species (C16GlcCer, C18GlcCer, and C24GlcCer) and Cer NS species (C16Cer,C18Cer, and C24Cer). Among the three GlcCer assayed, 13 C2,D2-GlcCer in keratinocytes showed marked increase in quantity along with increase in the concentration of 462 Osamu UEDA, et al.
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C2,D2-SPH added (Fig. 10A) . The amount of unlabeled GlcCer NS species, remained nearly unchanged regardless of 13 C2,D2-SPH addition, with a decreasing trend in the production of unlabeled compound when a final concentration of 10 -5 M was added (Fig. 10B) . The addition of SPH resulted in increased total GlcCer, which is unlabeled GlcCer and 13 C2,D2-GlcCer combined. Similarly, analyses of Cer also showed that the addition of 13 C2,D2-SPH increased the output of 13 C2,D2-Cer and raised the amount of total Cer (Fig. 10C, D) . These trends were observed regardless of the fatty acid carbon number.
Discussion
SPH, a messenger that regulates various cellular functions, is a digestive tract metabolite of GlcCer, a functional food component, and one of the active metabolites that have beneficial effect on the skin. This study was conducted to assess the disposition of SPH in vivo, particularly its dermal distribution at the target site, with the purpose of finding evidence in support of the beneficial effects of GlcCer to skin.
In mice which received an oral dose of 3 H-SPH, the concentration of radioactivity in blood peaked at 10.7 hr and decreased with a T1/2 of 88.60 hr. SPH was moderately absorbed and eliminated similarly to what was seen after an oral dose of Cer in a rat study 20) (Tmax 10.7 hr, T1/2 67.1 hr). The mass-balance study showed that the absorption rate was 30% or more based on the urinary excretion rate and the combined residual rate in the skin and carcass at 168 hr after dosing, and that 7.8% of the radioactivity remained in the body even after 168 hr following dosing. Such a slow clearance from the body and high residual rate may be partly attributable to the fact that SPH is available in the body in the form of an endogenous SPH pool or metabolites (e.g., sphingosine-1-phosphate, fatty acids and sphingolipids).
In the study to examine the tissue distribution after oral administration of 3 H-SPH, radioactivity was detected in all tissues and high concentration was specifically observed in the small intestine, liver, lung, large intestine, kidney, and spleen. The higher distribution of radioactivity in the small intestine and liver than other tissues was probably due to their functions; the small intestine is an organ participating in absorption and the liver is involved in the biosynthesis of sphingolipids. In addition, since the lung is the organ containing much sphingoid base, the dosed radioactive SPH was likely to replace endogenous SPH, resulting in higher radioactivity in this organ. 21) The radioactive concentration in the most tissues decreased along with blood concentration. Radioactive concentrations in the pancreas and white adipose tissue increased over time, peaking at 168 hr after dosing. Gatt reported that SPH is metabolized to fatty acids. 22) In particular, the white adipose tissue may contain fatty acids metabolized from SPH. These factors may have contributed to the high residual rate in the body observed in the massbalance assessment. As with blood concentration, radioactivity distributed to the skin also peaked at 12 hr after dosing and decreased over time to 168 hr. The ratio to plasma concentration was 4.6 at 12 hr after dosing but increased by more than 2-fold to 9.7 at 168 hr indicating the retention of radioactivity in the skin relative to that in the blood. Moreover, intracutaneous distribution showed a dermis radioactive concentration of 577.6 ng eq./g tissue at 12 hr, 5.8-fold higher than the epidermis concentration of 100.7 ng eq./g tissue but become lower than the epidermis concentration by 48 hr. The radioactive concentration in the epidermis increased gradually after 12 hr and held steady after 96 hr. Furthermore, the ratio of radioactivity in the epidermis to that in the skin was 1.0%, 7.8%, 10.1%, and 11.8%, respectively, at 12, 48, 96, and 168 hr after dosing, suggesting that radioactivity in SPH administered or its metabolites was moved from blood to the dermis and then from the dermis to epidermis.
HPLC analysis of the radioactivity distributed to the skin indicated the presence of unchanged SPH accounting for 16.5% in the skin at 12 hr. In addition, high polar metabolites considered to be fatty acids and their metabolites were also detected but most were metabolized to low polar compounds. SPH is an endogenous substance widely distributed in the body, and its metabolites of administrated SPH are indistinguishable from metabolites of endogenous SPH in the skin. A comparison with a standard reference by radio-HPLC in terms of retention time is not enough to enable identification of metabolites. Therefore, stable isotope-labeled SPH was administered to mice, and analyses of metabolites in the skin showed the presence in the skin of unchanged SPH and several species of stable isotope-labeled GlcCer and Cer. Other postulated metabolites such as fatty acids, SM and acylceramides 18) were not detected in this study. The detection of labeled sphingolipids in the skin after an oral dose of labeled SPH suggests that the SPH ingested indeed reached the skin and were converted to sphingolipids by biosynthesis.
A study of the biosynthesis of Cer from SPH in human keratinocytes showed the addition to the culture medium of various sphingoid bases, including SPH, phytosphingosine, and sphingadienine resulted in marked increase in intracellular and intra-medium levels of GlcCer and Cer containing the respective sphingoid base (data not shown). The biosynthetic pathway of GlcCer and Cer starts with a condensation reaction by serine palmitoyltransferase between L-serine and palmitoylCoA, followed by a ceramide synthase (CerS)-reaction between dihydrosphingosine and acyl-CoA to form dihydroceramide. There is question as to whether increase in GlcCer and Cer results from the effects of added SPH on these enzyme systems involved in the production of sphingolipids or whether GlcCer and Cer are biosynthesized from added SPH which merely plays a role as substrate. To elucidate the involvement of exogenous sphingoid bases in the increase of these intracellular sphingolipids, we labeled GlcCer and Cer with stable isotope using 13 C2,D2-SPH. It was found that GlcCer NS species and Cer NS species containing labeled SPH in their sphingoid base moiety were sphingolipids, which increased when 13 C2,D2-SPH was added. No change was observed in either endogenous GlcCer NS species and Cer NS species not containing the stable isotope or Cer species containing phytosphingosine or sphingadienine in stead of SPH in their sphingoid base moiety. On the basis of these results, we conclude that increase in intracellular sphingolipids observed when sphingoid base was added to human keratinocytes is not caused by the effect of sphingoid base on the enzyme systems involved in the sphingolipids production, but by increase in GlcCer and Cer due to the role of sphingoid base as the substrate of CerS. The results of the in vitro study described above indicate that the effect of SPH on the enzyme systems is none or negligible in the in vivo system too and that the biosynthesis of GlcCer and Cer from SPH which trans-ferred to the skin may lead to increase in total Cer in the skin. The amount of 13 C2,D2-GlcCer and 13 C2,D2-Cer detected in the skin of mice dosed with 13 C2,D2-SPH comprised approximately 1% of the amount of endogenous GlcCer and Cer. Since the mice used in this study were normal and healthy, a normal amount of Cer already existed in the skin already. If a pathological animal model is used, whose Cer decreases due to aging or atopic dermatitis, we can predict the possibility of increase in the existing rate of sphingolipids to which stable isotope is introduced.
CerS have known substrate specificity for chain lengths of acyl-CoA, and CerS2-CerS6 have been found in the epidermis. 23) The fatty acid of the Cer detected in the largest amount in human keratinocytes was the one with a carbon number of 16, followed by fatty acids with a carbon number of 24, 22, and 26 and those with carbon numbers of 14, 18, and 20 found only in trace amounts. Therefore, CerS5 and CerS6 that use palmitoyl-CoA as substrate are considered to play large roles in Cer biosynthesis from SPH in skin.
The above results show that SPH is absorbed by the gastrointestinal tract and distributed to the skin and that it moves from the dermis to the epidermis in the skin. SPH was partly distributed to the skin in unchanged form, and some distributed compounds were converted to GlcCer and Cer species by biosynthesis. In conclusion, when GlcCer is taken as functional food, it is metabolized in the gastrointestinal tract or in the body to a sphingoid base which in turn is distributed in the skin. Then, the sphingoid base is biosynthesized to Cer, thereby enhancing the barrier function of the skin. There is the possibility that Cer thus formed has improvement effect on the skin caused by the inhibitory action on increase in IL-1a, or enhanced production of the cornified envelope, etc. 24) 
